These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24877605)

  • 1. The role of formulation on the pharmacokinetics of antiretroviral drugs.
    Bastiaans DE; Cressey TR; Vromans H; Burger DM
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1019-37. PubMed ID: 24877605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
    Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
    Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.
    Timmins P; Brown J; Meanwell NA; Hanna GJ; Zhu L; Kadow JF
    Drug Discov Today; 2014 Sep; 19(9):1288-93. PubMed ID: 24727410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line antiretroviral treatment of HIV-infected children. A choice largely based on adult data.
    Prescrire Int; 2011 Apr; 20(115):101-4. PubMed ID: 21648216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.
    Van Gyseghem E; Pendela M; Baert L; Rosier J; Van 't Klooster G; De Man H; Bouche MP; Schueller L; Van Remoortere P; Wigerinck P; Adams E; Hoogmartens J; Van den Mooter G
    Eur J Pharm Biopharm; 2008 Nov; 70(3):853-60. PubMed ID: 18657611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
    Taupitz T; Dressman JB; Klein S
    Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.
    van der Flier M; Verweel G; van der Knaap LC; van Jaarsveld P; Driessen GJ; van der Lee M; Hartwig NG; Burger DM
    Antivir Ther; 2008; 13(8):1087-90. PubMed ID: 19195335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.
    Piana C; Danhof M; Della Pasqua O
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):497-511. PubMed ID: 28043170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients.
    Gervasoni C; Baldelli S; Cerea M; Cenderello G; Bini T; Vimercati S; Iardino R; Gazzaniga A; DʼArminio Monforte A; Clementi E; Cattaneo D
    Ther Drug Monit; 2016 Jun; 38(3):420-2. PubMed ID: 26727626
    [No Abstract]   [Full Text] [Related]  

  • 13. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
    Gerber JG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating an HIV-infected paediatric patient: an easy task?
    Rakhmanina NY; van den Anker JN
    Antivir Ther; 2010; 15(3):293-6. PubMed ID: 20516549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.
    Phelps BR; Rakhmanina N
    Paediatr Drugs; 2011 Jun; 13(3):175-92. PubMed ID: 21500872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India.
    Ramachandran G; Kumar AK; Vasantha M; Shah I; Swaminathan S
    Indian Pediatr; 2010 Oct; 47(10):890-1. PubMed ID: 21048244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.
    Llibre JM; Arribas JR; Domingo P; Gatell JM; Lozano F; Santos JR; Rivero A; Moreno S; Clotet B;
    AIDS; 2011 Sep; 25(14):1683-90. PubMed ID: 21673556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
    Stephan C; León W
    HIV Med; 2014 Feb; 15(2):124-8. PubMed ID: 24112515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.